Back to Research Hub
Telix Pharmaceuticals Limited
TLX
$9.41+0.19 (+2.06%)
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States.
StreetsValue research for Telix Pharmaceuticals Limited (TLX)
Members get the full report for Telix Pharmaceuticals Limited: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.